Please use this identifier to cite or link to this item:
|Title:||Oxaliplatin/Fluorouracil/Leucovorin in Advanced Colorectal Carcinoma: An Asian Experience|
|Authors:||Lim, E.H. |
|Source:||Lim, E.H., Lim, R.S.C., Wu, T.S., Kong, H.L. (2003-12). Oxaliplatin/Fluorouracil/Leucovorin in Advanced Colorectal Carcinoma: An Asian Experience. Annals of Pharmacotherapy 37 (12) : 1909-1912. ScholarBank@NUS Repository. https://doi.org/10.1345/aph.1D153|
|Abstract:||BACKGROUND: Oxaliplatin/fluorouracil/leucovorin (FOLFOX4) is an effective and generally well-tolerated regimen in Western studies of metastatic colorectal carcinoma. OBJECTIVE: To evaluate the objective tumor responses and toxicities of the FOLFOX4 regimen in a predominantly Chinese population with advanced colorectal carcinoma in Singapore. METHODS: Forty-seven consecutive patients were enrolled in a retrospective study between March 1998 and December 2001. FOLFOX4 was first-line treatment in 36% of these patients, second-line in 36%, third-line in 17%, and fourth-line in 11%. Tumor responses were assessed radiologically, and toxicities were graded by the National Cancer Institute common toxicity system. RESULTS: The objective response rate (all partial responses) was 45%, and stable disease was achieved in 35% of the patients. There were no deaths due to toxicity. Mild to moderate peripheral sensory neuropathy affected half of the patients, with 1 report of cold exacerbation in this tropical series. The rate of hypersensitivity reactions to oxaliplatin was 11%, and they usually occurred late in the treatment course. CONCLUSIONS: FOLFOX4 has good efficacy in metastatic colorectal carcinoma in our local population, but the rate of hypersensitivity reactions to oxaliplatin was high.|
|Source Title:||Annals of Pharmacotherapy|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 17, 2018
WEB OF SCIENCETM
checked on Nov 18, 2017
checked on Jan 14, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.